To address some of these gaps, this study aims to further evaluate the impact of NLRP3 inhibition on single‐agent and combination chemotherapy‐induced adverse effects, chemotherapy efficacy, and cancer progression in NSG mice engrafted with pediatric ALL patient‐derived xenograft (PDX). The gene discussed is NLRP3; the disease is acute lymphoblastic leukemia.